Related Experiment Video
Updated: Nov 8, 2025
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.8K
[Myofasciitis under nivolumab treatment]
M Krusche1, U Schneider2, C Geisler3
1Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité - Universitätsmedizin, Charitéplatz 1, 10117, Berlin, Deutschland. martin.krusche@charite.de.
Zeitschrift Fur Rheumatologie
|April 22, 2021
Summary
A melanoma patient on nivolumab developed dermatosclerosis and myalgia, diagnosed as myofasciitis. Treatment was paused, and immunosuppressants initiated, highlighting rare immune-related adverse events.
Area of Science:
- Oncology
- Rheumatology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) like nivolumab are crucial in cancer therapy.
- ICIs can cause immune-mediated adverse events (imAEs), sometimes mimicking rheumatological conditions.
- Dermatosclerosis and myofasciitis are rare but serious potential imAEs.
Observation:
- A 73-year-old female melanoma patient developed rapidly progressive dermatosclerosis and myalgia during nivolumab treatment.
- Clinical presentation included flexion contractures.
- Imaging and biopsy confirmed a diagnosis of myofasciitis.
Findings:
- Nivolumab treatment was paused due to the observed adverse events.
- Initiation of methotrexate and prednisolone was part of the management strategy.
- This case underscores the potential for ICIs to induce myofasciitis.
Implications:
- Close interdisciplinary collaboration between oncologists and rheumatologists is essential for managing ICI-induced imAEs.
- Awareness of rare imAEs like myofasciitis is critical for timely diagnosis and treatment.
- Understanding these rare side effects can improve patient outcomes and treatment protocols for cancer patients receiving ICIs.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
2.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.3K
01:14Myocarditis III: Medical Management
46
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
46
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
304
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
304
01:22Myocarditis IV: Nursing Management
81
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
81
01:25Pericarditis IV: Nursing Management
132
Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
132
01:17Pericarditis III: Medical Management
86
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
86